Good Intelligence Participates in Bio Korea... "Application of Drug Repositioning and Biobetter Development"

[Asia Economy Reporter Hyungsoo Park] Good Intelligence, an AI bio venture company that derives new drug candidate substances using big data and artificial intelligence (AI), announced on the 9th that it will participate in ‘Bio Korea 2022,’ held for three days from the 11th to the 13th at COEX in Seoul.

Bio Korea, Asia’s largest international health industry convention, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as consulting firms, academia, and related organizations from both domestic and overseas participate.

At Bio Korea, Good Intelligence will register for partnering attended by multinational companies, world-leading bio companies, and investment institutions to seek technology agreements with multinational pharmaceutical companies. They will promote their drug repositioning platform technology ‘RepoGItion’ and bio-better technology using 3D modeling. Good Intelligence is a platform company that provides solutions to high-tech companies and experts, including bio companies. They are developing technology in two fields that combine bio and AI.

The first field developed by Good Intelligence is drug repositioning. CEO Ju-Young Lee expects that the world’s best combinatorial optimization technology (CSA technology) he possesses will be a game changer in new drug development using drug repositioning.

Good Intelligence focuses on applying its proprietary CSA technology to drug development, especially the repositioning and repurposing of already developed drugs. This method is expected to play a key role in reducing the time and cost of new drug development by using drugs already known to be safe, thereby reducing risk.

The other field is bio-better new drug development. The main goal is to develop bio-betters that respond more efficiently to target substances compared to existing biologics through protein folding and protein structure prediction, which CEO Ju-Young Lee has researched for nearly 30 years.

Since bio-betters target blockbuster drugs as biologics, the industrial value associated with this field is expected to be significant. In particular, one of the bio-better candidates currently being developed by Good Intelligence has shown greater activity than existing biologics, making this a particularly promising area.

Ju-Young Lee, CEO of Good Intelligence, earned a Ph.D. in physics under the guidance of Professor John Michael Kosterlitz, the 2016 Nobel Prize in Physics laureate. Since 1994, he has focused his research on solving protein folding problems. Using his unique combinatorial optimization technology, he participated in the Critical Assessment of protein Structure Prediction (CASP) competition and won first place consecutively in the Template-Based Modeling (TBM) category in 2014 and 2016.

A Good Intelligence official said, "At Bio Korea, we plan to inform the world that there are excellent AI-based bio companies in Korea and maintain continuous exchanges." They added, "We plan to collaborate with domestic and foreign pharmaceutical companies to propose repositionable drugs and develop bio-better biologics that align with recent trends."

This content was produced with the assistance of AI translation services.